Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2022-12-31 · accession 0001567619-23-000329 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-04 | 2022-12-31 | PCSA | Yorke Justin W | Dir | A - Grant | — | +18.2K | 33.1K | +122% | — |
| D | 2023-01-04 | 2023-01-01 | PCSA | Yorke Justin W | Dir | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-31 | A | A | 18,208 | — | 33,093 | D | — | — | (F1) Vesting of time-based restricted shares. |
| 2 | Derivative | Restricted Stock | 2023-01-01 | A | A | 30,000 | $0.00 | 30,000 | D | $0.00 · — to — | 30,000 Common Stock | (F2) The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. |